SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home â–¸ Brochures
Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Syngene offers integrated and standalone services across the drug discovery continuum from Target Identification to IND enabling.
Syngene’s offers an end-to-end platform to deliver integrated and standalone services for small molecules across the Development continuum.
Syngene’s data consortium comprises a group of consenting clients working towards enabling greater learning and creating superior mathematical models for more informed decisions in their projects.
Syngene’s Target Identification and Validation services combine data, informatics, and knowledge about biological target assays for holistic target assessment and risk mitigation in drug discovery.
Syngene, with its comprehensive suite of DMPK profiling assays, can help you achieve a high rate of success with your clinical candidates across drug modalities.
Syngene’s Chemistry process research lab acts as a bridge between drug discovery and development when faster delivery of chemical compounds is required – mg to kg.
Syngene offers the full range of IND-enabling Exploratory and GLP Tox studies for small molecules and biologics.
Syngene offers complete value-chain process research and development services across novel chemical entities, APIs, and advanced intermediates – route-scouting to commercial manufacturing.
Syngene offers Formulation Development services for oral solids, liquids, and injectable forms, including integrated services focusing on quality, speed, and cost-efficiency.
Syngene’s Sterile Fill-Finish facility is custom-built to meet market demand for clinical supply of sterile drug products having short development timelines.
Syngene has one of the largest Analytical facilities in Asia. The facility supports small molecules and biologics programs from early development to CMC filing and commercialization.
Syngene’s Center of Excellence for Nitrosamine impurity testing supports formulation requirements for small molecule APIs, key sourcing materials, and intermediates.
One of the largest Stability facilities in Asia, Syngene supports both small molecules and biologics from early development to CMC
Syngene offers end-to-end Biologics Development and Manufacturing solutions for mammalian and microbial systems, including Viral Testing and Sterile Fill-Finish. We also have the expertise to move from Gene to GMP in 10 months.
Syngene offers end-to-end and integrated solutions for PROTACs ranging from early proof-of-concept studies to identifying a development candidate.
Syngene’s services encompass therapeutic oligonucleotides, diagnostic oligonucleotides, enzymatic synthesis, and analytical services.
Syngene has a well-defined system that delivers across all aspects of Supply Chain Management, ranging from planning and inventory to sourcing, procurement, logistics, performance, safety, and compliance.
© 2024. Syngene International Limited